| Issuer: | Appili Therapeutics Inc. |
| Securities: | Class A common shares |
| Symbol(s): | APLI |
| Delisting Review Type: | Remedial |
| Delisting Review Period: | 120 days to regain compliance with continued listing requirements. |
| TSX Contact: | Anne Child, Managing Director, TSX Listings |
TMX Group Limited and its affiliates (the “TMX group of companies”) do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. Please seek professional advice to evaluate specific securities or other content on this site. All content (including any links to third party sites) is provided for informational purposes only (and not for trading purposes), and is not intended to provide legal, accounting, tax, investment, financial or other advice and should not be relied upon for such advice. The views, opinions and advice of any third party reflect those of the individual authors and are not endorsed by the TMX group of companies. The TMX group of companies have not prepared, reviewed or updated the content of third parties on this site or the content of any third party sites, and assume no responsibility for such information.
